ASH Iron Deficiency Cost-Effectiveness Report
Generated 6/25/2026, 4:41:19 PM · Format: exec · Scope: current
Executive summary
For a cohort of 10,000 general us adults at a willingness-to-pay threshold of $100,000 per QALY, the preferred diagnostic strategy is Ferritin ≤50 ng/mL, the preferred treatment strategy is Upfront IV iron, and the preferred care pathway is Aggressive detection and faster treatment.
Scenario assumptions
| Population | General US adults |
| Cohort size | 10,000 |
| Prevalence | 12.0% |
| Perspective | Healthcare system |
| Time horizon | 1 year(s) |
| WTP threshold | $100,000 / QALY |
Cost & outcome results
| Module | Preferred | Total cost | QALYs | NMB |
|---|---|---|---|---|
| Diagnostic | Ferritin ≤50 ng/mL | $765,016 | 47.04 | $3.94M |
| Treatment | Upfront IV iron | $18.35M | 399.80 | $21.63M |
| Pathway | Aggressive detection and faster treatment | $2.40M | 43.73 | $1.98M |
Sensitivity summary
Tornado analysis indicates results are most sensitive to missed-diagnosis cost, utility gain, and unnecessary-treatment cost. Threshold analysis across willingness-to-pay values from $50,000 to $200,000 per QALY supports robustness of the preferred strategy in this scenario.
Limitations
Results are generated from an illustrative deterministic prototype model. They should not be interpreted as final clinical, policy, or economic conclusions.